Similar articles

• Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

  Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Prandoni P, et al. Lancet. 1992 Feb 22;339(8791):441-5. doi: 10.1016/0140-6736(92)91054-c. Lancet. 1992. PMID: 1346817 Clinical Trial.
• Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.

  [No authors listed] [No authors listed] Arch Orthop Trauma Surg. 1992;111(2):110-20. doi: 10.1007/BF00443477. Arch Orthop Trauma Surg. 1992. PMID: 1314065 Clinical Trial.
• Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins?

  Agnelli G. Agnelli G. Haematologica. 1995 Mar-Apr;80(2 Suppl):78-83. Haematologica. 1995. PMID: 7628776 Review. No abstract available.
• Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

  Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety. Breddin HK, et al. N Engl J Med. 2001 Mar 1;344(9):626-31. doi: 10.1056/NEJM200103013440902. N Engl J Med. 2001. PMID: 11228276 Clinical Trial.
• Prophylaxis of postoperative deep vein thrombosis in general surgery: experiences with Fragmin.

  Bergqvist D. Bergqvist D. Acta Chir Scand Suppl. 1988;543:87-9. Acta Chir Scand Suppl. 1988. PMID: 2847463 Review. No abstract available.